Citigroup Inc Aadi Bioscience, Inc. Transaction History

Citigroup Inc

$169 Billion
Q3 2024

A detailed history of Citigroup Inc transactions in Aadi Bioscience, Inc. stock. As of the latest transaction made, Citigroup Inc holds 81 shares of AADI stock, worth $247. This represents 0.0% of its overall portfolio holdings.

Number of Shares

Previous 2,757 97.06%

Holding current value

$247

Previous $4,000 100.0%

% of portfolio

0.0%

Previous 0.0%

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 12, 2024	SELL	$1.32 - $2.06 $3,532 - $5,512	-2,676 Reduced 97.06%	81 $0
Q2 2024 Aug 12, 2024	SELL	$1.46 - $2.31 $1,226 - $1,940	-840 Reduced 23.35%	2,757 $4,000
Q1 2024 May 10, 2024	BUY	$1.59 - $2.44 $2,027 - $3,111	1,275 Added 54.91%	3,597 $8,000
Q4 2023 Feb 09, 2024	BUY	$1.97 - $5.41 $3,750 - $10,300	1,904 Added 455.5%	2,322 $4,000
Q3 2023 Nov 09, 2023	SELL	$4.84 - $7.13 $21,387 - $31,507	-4,419 Reduced 91.36%	418 $2,000
Q2 2023 Aug 10, 2023	BUY	$6.84 - $8.56 $33,078 - $41,396	4,836 Added 483600.0%	4,837 $33,000
Q1 2023 May 11, 2023	SELL	$6.85 - $13.0 $671 - $1,274	-98 Reduced 98.99%	1 $0
Q4 2022 Feb 09, 2023	SELL	$11.99 - $14.5 $1,450 - $1,754	-121 Reduced 55.0%	99 $1,000
Q3 2022 Nov 10, 2022	SELL	$12.03 - $14.22 $210,152 - $248,409	-17,469 Reduced 98.76%	220 $3,000
Q2 2022 Aug 10, 2022	SELL	$11.57 - $17.92 $96,031 - $148,736	-8,300 Reduced 31.94%	17,689 $218,000
Q1 2022 May 12, 2022	SELL	$16.65 - $24.97 $169,447 - $254,119	-10,177 Reduced 28.14%	25,989 $441,000
Q4 2021 Feb 10, 2022	BUY	$19.32 - $29.02 $686,207 - $1.03 Million	35,518 Added 5481.17%	36,166 $873,000
Q3 2021 Nov 10, 2021	BUY	$25.52 - $41.85 $16,536 - $27,118	648 New	648 $19,000

Others Institutions Holding AADI

# of Institutions

Shares Held

12.6M

Call Options Held

23.8K

Put Options Held

View Full List

About Aadi Bioscience, Inc.

Ticker AADI
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 21,016,800
Market Cap $64.1M
Description
Aadi Bioscience, Inc., a clinical-stage biopharmaceutical company, engages in developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes. Its lead drug candidate, FYARRO is a form of sirolimus bound to albumin. Aadi is evaluating FYARRO in cancers with known mTOR pathway activation, ...

More about AADI

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Citigroup Inc, based on Form 13F filings with the SEC.

News

Stay updated on Citigroup Inc with notifications on news.

Account